Literature DB >> 17044828

Starting and stopping treatment for seizures and epilepsy.

David Chadwick1.   

Abstract

Decisions about when to start or to stop antiepileptic drug (AED) treatment must be informed by reliable information of the natural history of epilepsy, the effect of treatment, and the social context of the individual. Ultimately the patient will be the decision maker, the clinician or health-care professional, the provider and interpreter of information. While observational studies will provide information on natural history, the most reliable information on the effect of intervention will come from randomised controlled trials in relevant populations of patients. However, these need to be large enough to allow interpretation not just of the average effect across the recruited patients, but also some estimate of the effects for an individual based on the prognostic effects that most effect outcomes. When trials are of sufficient size they can allow the development of predictive models that assist decision making. The Medical Research Council studies of AED withdrawal and early epilepsy and single seizures provide examples of such trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17044828     DOI: 10.1111/j.1528-1167.2006.00662.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

1.  Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas.

Authors:  Rohit R Das; Elinor Artsy; Shelley Hurwitz; Patrick Y Wen; Peter Black; Alexandra Golby; Barbara Dworetzky; Jong Woo Lee
Journal:  J Neurooncol       Date:  2012-01-03       Impact factor: 4.130

2.  Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US.

Authors:  Linda Kalilani; Edward Faught; Hyunmi Kim; Chakkarin Burudpakdee; Arpamas Seetasith; Scott Laranjo; David Friesen; Kathrin Haeffs; Victor Kiri; David J Thurman
Journal:  Neurology       Date:  2019-04-10       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.